Search
Search Results
##search.searchResults.foundPlural##
-
HIGH SERUM ERYTHROPOIETIN AND FERRITIN LEVELS ASSOCIATED WITH ANEMIA RESPONSE IN MALIGNANT LYMPHOMA
1455PDF: 763HTML: 2822cover letter: 178 -
-
Anemia in the elderly: not always what it seems.
3235PDF: 987HTML: 1752Figure 1: 158Figure 1 revised: 163 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
3977PDF: 1875HTML: 1746 -
COEXISTENCE OF MULTIPLE GENE VARIANTS IN SOME PATIENTS WITH ERYTHROCYTOSES Multiple gene variants in erythrocytosis
777PDF: 1194HTML: 116 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1869PDF: 706HTML: 678 -
OUTLINE OF IRON METABOLISM, WITH EMPHASIS TO ERYTHROID CELLS iron Metabolism
1706PDF: 831Html: 277 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1306PDF: 1380PDF: 986HTML: 187 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
1951PDF: 574Suppl. Files: 271HTML: 150 -
ULTRASOUND AS FIRST LINE STEP IN ANAEMIA DIAGNOSTICS
1311PDF: 854HTML: 1759 -
-
-
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
988PDF: 931HTML: 302 -
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy
2713PDF: 728HTML: 1243Blood Count trend before and during lenalidomide treatment: 154Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 169 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3308PDF: 1263HTML: 1849Fig.1: 182Fig. 2: 188 -
EXTREMELY OLD PATIENTS HOSPITALIZED IN INTERNAL MEDICINE: WHAT ABOUT THEIR ANEMIA? Anemia in the elderly
1456PDF: 472HTML: 203 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2092PDF: 1131HTML: 2572Study of serum haptoglobin level in thalassemia: 317Figures: 158 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2401PDF: 759HTML: 1721 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2516PDF: 775HTML: 5175 -
PERIOPERATIVE MANAGEMENT OF SICKLE CELL DISEASE: A NARRATIVE REVIEW
7826PDF: 3176HTML: 1175 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1929PDF: 1360HTML: 246 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2500PDF: 803HTML: 14928Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 273 -
PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome
1008PDF: 734HTML: 271 -
Thalidomide treatment for thrombocytopenia secondary to hypersplenism in children with β-thalassemia major: a case series Thalidomide treatment for thrombocytopenia
838PDF: 695HTML: 96 -
DIAMOND BLACKFAN ANEMIA: A TERTIARY CARE CENTRE EXPERIENCE
1758PDF: 830HTML: 3581Diamond Blackfan Anemia: A Tertiary care centre experience: 230 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1555PDF: 720HTML: 223 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1165PDF: 732HTML: 296 -
PATHOGENESIS OF MALARIA IN TISSUES AND BLOOD
4337PDF: 1872HTML: 17710







